Icosavax, Inc. (ICVX): Price and Financial Metrics
ICVX Price/Volume Stats
| Current price | $15.31 | 52-week high | $16.10 |
| Prev. close | $15.45 | 52-week low | $4.75 |
| Day low | $15.28 | Volume | 9,315,200 |
| Day high | $15.44 | Avg. volume | 1,215,776 |
| 50-day MA | $15.08 | Dividend yield | N/A |
| 200-day MA | $10.06 | Market Cap | 766.88M |
ICVX Stock Price Chart Interactive Chart >
Icosavax, Inc. (ICVX) Company Bio
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-A12, an respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-121, a vaccine candidate with RSV target; IVX-241, a vaccine candidate with hMPV target; IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2^ target indication; and IVX-421, a variant RBD antigen with SARS-CoV-2^ target indication. The company was incorporated in 2017 and is headquartered in Seattle, Washington.
Latest ICVX News From Around the Web
Below are the latest news stories about ICOSAVAX INC that investors may wish to consider to help them evaluate ICVX as an investment opportunity.
Chief Medical Officer Niranjan Kanesa-thasan Sells 11,884 Shares of Icosavax Inc (ICVX)According to a recent SEC filing, Niranjan Kanesa-thasan, the Chief Medical Officer of Icosavax Inc (NASDAQ:ICVX), sold 11,884 shares of the company on December 20, 2023. |
Insider Sell Alert: Chief Business Officer Cassia Cearley Sells 8,759 Shares of Icosavax Inc (ICVX)In a recent transaction on December 13, 2023, Cassia Cearley, the Chief Business Officer of Icosavax Inc (NASDAQ:ICVX), sold 8,759 shares of the company's stock. |
Pharma Stock Roundup: PFE Issues Weak 2024 View, AZN to Buy Icosavax & MorePfizer (PFE) issues a disappointing outlook for 2024. AstraZeneca (AZN) announces that it is buying vaccine company, Icosavax. |
Icosavax, Inc. (ICVX) Moves to Buy: Rationale Behind the UpgradeIcosavax, Inc. (ICVX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
Icosavax, Inc. (ICVX) Is Up 0.10% in One Week: What You Should KnowDoes Icosavax, Inc. (ICVX) have what it takes to be a top stock pick for momentum investors? Let's find out. |
ICVX Price Returns
| 1-mo | N/A |
| 3-mo | 0.13% |
| 6-mo | 157.31% |
| 1-year | 178.87% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -2.86% |
| 2023 | 98.49% |
| 2022 | -65.30% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...